Copy
View this email in your browser
IN THIS ISSUE
Walter Reed National Military Medical Center Enters into Routine Use of the INTERCEPT Blood System Versiti Affiliates Become the Latest BCA Members to Sign an Agreement for the Use of INTERCEPT | Cerus  Workshop at SCABB Annual Meeting, June 2, 2016 Challenges to Blood Transfusion due to Zika Virus Highlighted in The Lancet Science Section: What We're Reading | Calendar of Events
Walter Reed National Military Medical Center Enters into Routine Use of the INTERCEPT Blood System
Walter Reed, a component of the Armed Services Blood Program, has begun routine use of the INTERCEPT Blood System for apheresis platelets. Walter Reed transfuses approximately 1,000 apheresis platelet units annually. Similar to the National Institutes of Health, Walter Reed has decided to convert 100% of their platelet production to now be pathogen-reduced using INTERCEPT.
Versiti Affiliates Become the Latest BCA Members to Sign an Agreement for the Use of INTERCEPT
Versiti has signed an agreement for use of the INTERCEPT Blood System for platelets and plasma. Versiti is a strategic affiliation comprised of the Blood Center of Wisconsin, Heartland Blood Centers, Indiana Blood Center, and Michigan Blood with the vision to improve the health of patients as a national leader in innovative transfusion solutions for healthcare systems. Versiti affiliates are also members of Blood Centers of America (BCA), a member-owned organization comprised of nearly 50 independent blood centers throughout North America that account for more than 30% of the US blood supply.
Cerus Workshop at SCABB Annual Meeting June 2, 2016: Safety and Sustainability of the US Blood Supply in the Era of Emerging Pathogens
Current safety measures have significantly improved the safety of the US blood supply, largely due to the implementation of screening for blood-borne pathogens such as HIV, HBV and HCV. Yet, it’s become increasing evident that new pathogens are rapidly emerging; examples of such outbreaks include chikungunya, dengue and Zika. A host of challenges arise in light of such outbreaks including potentially stopping collections and importing blood products, effectively identifying geographic areas impacted, and the complexity inherent in “triggering” safety measures with seasonal pathogens. This workshop will explore such challenges, as well as the measures that have been considered as part of emergency preparedness planning.

Learn more about the SCABB annual meeting
Challenges to Blood Transfusion due to Zika Virus Highlighted in The Lancet
A recent publication in “The Lancet” warns that, due to the high rate of Zika virus cases that are asymptomatic, the utility of blood donor deferrals may be limited. The authors recommend focusing efforts in areas lacking the capacity to provide Zika-safe blood to all patients to concentrate on at-risk recipients, including pregnant women and women undergoing a high number of transfusions, such as those with sickle cell disease. In addition, they emphasize the urgent need to further develop pathogen reduction systems for whole blood and red blood cells, and/or nucleic acid testing (NAT) assays to screen all donated blood.

Musso D, Stramer S, Busch M. "Zika virus: a new challenge for blood transfusion" The Lancet 2016;387(10032);1993-1994

Read the article


 
Science Section: What We’re Reading

Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland.
Niederhauser C, et al. Transfusion Medicine and Hemotherapy, 2016. 
Read the abstract

Zika Virus: The Latest Newcomer
Saiz J, et al. Frontiers in Microbiology, 2016 April.
Read the abstract

Dengue Virus Antibodies Enhance Zika Virus Infection
Paul LM, et al. bioRxiv 2016 April.
Read the article
 
Zika virus: new emergencies, potential for severe complications, and prevention of transfusion-transmitted Zika fever in the context of co-circulation of arboviruses
Musso D, et al. Blood Transfusion 2016 January.
Read the letter

 
Calendar of Events

SCABB (South Central Association of Blood Banks)
June 2-6, 2016 | Houston, TX

Additional Information

   Join us for an industry workshop at SCABB:
   Safety and Sustainability of the US Blood Supply in the Era of Emerging Pathogens
   June 2, 2016 | 3:30PM - 4:30PM | OMNI Houston

BBANYS (Blood Bank Association of New York State) Annual Meeting
June 9-10 | Albany, NY
Additional Information


AABB (American Association of Blood Banks)
Zika Virus Symposium: Blood & HCT/P Safety

June 10, 2016  |  Washington, DC

Additional Information

ABC Summer Meeting
August 2-4, 2016 | Honolulu, HI
Additional Information

 
SABM Annual Meeting (Society for the Advancement of Blood Management)
September 29 - October 1, 2016 | Grand Rapids, Michigan
Additional Information


AABB (American Association of Blood Banks) Annual Meeting
October 22-25, 2016 | Orlando, FL
Additional Information


ASA Annual Meeting (American Society of Anesthesiologists)
October 22-25, 2016 | Chicago, IL

Additional Information
Data for pathogen reduction of ZIKA by the INTERCEPT Blood System, pathogen reduction system, has not been submitted for FDA review.

There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.

CONTRAINDICATIONS: Contraindicated for preparation of plasma and platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet and plasma components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS and PRECAUTIONS: Only INTERCEPT Processing Sets for platelets and plasma are approved for use with the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet and plasma components. No other source of UVA light may be used. Please refer to the Operator's Manual for the INT100 Illuminator. Discard any platelet or plasma components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl) phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

PLATELETS: INTERCEPT processed platelets may cause the following adverse reaction: Acute Respiratory Distress Syndrome (ARDS). An increased incidence of ARDS was reported in a randomized trial for recipients of INTERCEPT processed platelets, 5/318 (1.6%), compared to recipients of conventional platelet components (0/327). Monitor patients for signs and symptoms of ARDS.


PLASMA: Amotosalen-treated plasma may cause the following adverse reaction Cardiac Events. In a randomized controlled trial of therapeutic plasma exchange (TPE) for TTP, five patients treated with INTERCEPT Blood System processed plasma and none with conventional plasma had adverse events in the cardiac system organ class (SOC) reported. These events included angina pectoris (n=3), cardiac arrest (n=1), bradycardia (n=1), tachycardia (n=1) and sinus arrhythmia (n=1). None of these events resulted in documented myocardial infarction or death. Monitor patients for signs and symptoms of cardiac events during TPE for TTP.

Rx only. For full prescribing information, please see package insert.
MKT-EN 00165-09
Copyright © 2016 Cerus Corporation, All rights reserved.
Cerus, INTERCEPT Blood System and INTERCEPT are registered trademarks of Cerus Corporation.

Our mailing address is:
Cerus Corporation
1220 Concord Avenue
Concord, California 94520

Add us to your address book


unsubscribe from this list    update subscription preferences